Kodiak Sciences Inc.
KOD
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$32.89
Price+0.06%
$0.02
1Y
Price
Market Cap
$2.058b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$241.994m
-5.2%
1y CAGR-1.1%
3y CAGR+4.7%
5y CAGREPS
-$4.19
+3.0%
1y CAGR+2.2%
3y CAGR+7.2%
5y CAGRBook Value
$61.096m
$256.811m
Assets$195.715m
Liabilities$95.701m
DebtDebt to Assets
37.3%
-0.4x
Debt to EBITDAFree Cash Flow
-$159.902m
-17.1%
1y CAGR+2.2%
3y CAGR+7.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company